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text. For example, microfilaments are incor-
rectly introduced as being “~35 nm in diam-
eter,” but the same chapter subsection also
provides the correct relative diameters of
microtubules  and  intermediate  filaments.
Perhaps subsequent editions of the textbook
will address these issues.
The strength of the textbook lies in its
ability to promote active learning by apply-
ing acquired physiological knowledge to
clinical cases. The initial case and open-
ended questions of each section, as well as
case-based  “Applying  What You  Know”
questions at the end of each chapter, are en-
gaging even for the non-medical student and
provide a broad conceptual framework that
helps the reader fit pieces of information to-
gether. Importantly, answers to all questions
and a concise case analysis from both clini-
cal and physiological perspectives are given
at the end of each section. Furthermore, an
access code is provided for a supplementary
interactive  online  study  aid,  Wink-
ingSkull.com PLUS, which includes two ad-
ditional clinical cases on the cardiovascular
and  respiratory  systems  and  814  images
from the Atlas of Anatomy with a timed test
feature. The online program also gives read-
ers the option of displaying anatomy labels
in English or Latin. Taken together, these
qualities make Fundamentals of Medical
Physiology a valuable resource. 
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Small Molecular Therapy for Genetic
Diseases is a collection of articles that com-
memorate the Orphan Drug Act that was
passed in 1983 after sustained effort from pa-
tient advocacy groups. The legislation gave
pharmaceutical  companies  various  incen-
tives, such as tax credits, expedited review,
flexible clinical trial requirements, and ex-
clusive marketing to develop treatments that
would otherwise be unprofitable. A recent
search in the on-line Orphan Drug database
(http://www.accessdata.fda.gov/scripts/opdli
sting/oopd/index.cfm) reveals that 370 drugs
have been approved for 180 diseases, with
approximately  2,000  more  drugs  in  the
pipeline. This turnout makes former Office
of  Orphaned  Drugs  Director  Marlene
Haffner proudly conclude at the end of the
first chapter that the “taxpayer’s dollars have
been well spent.” The majority of the ap-
proved products are biological agents such
as enzymes, antibodies, or hormones. An-
other significant portion of drugs are cyto-
toxic agents for malignancies or autoimmune
diseases. Only 24 agents are small molecule
drugs for genetic diseases, but it is this cate-
gory of drugs that provides the focus for the
rest of the book. Although macromolecular
therapy  may  dominate  the  post-genomic
world, the authors remind us that small mol-
ecules have many distinct advantages, such
as easy delivery, straightforward pharmaco-
kenitics, and minimal immune interactions.
After an introductory section covering
legislative backgrounds, infrastructures, and
pharmacology principles, the book reviews
11 examples of effective small molecule
therapy. They are grouped by the molecules’
modality of action as co-factors of enzy-
matic  activities,  activators  of  alternative
pathways to circumvent metabolic defects,
and metal conjugates. In each chapter, an
overview of the pathogenesis and epidemi-
ology of the condition is followed by clini-
cal trial and case study data of the drug. 
The book targets three types of readers:
clinicians and clinical scientists, patients and
patient advocates, and policy makers. The
sense of hope and encouragement that per-
meates the pages enables the book to moti-
vate physicians and researchers to use and
develop  small  molecule  therapies.  But
someone familiar with biomedical sciences
will likely find the articles rather rudimen-
tary. Although the writing is void of jargon
and explains the clinical data in more palat-
able terms than a Cochran Review, it would
be helpful to know what scientific inquiriesBook reviews 162
led to these therapies and to see more mo-
lecular details of both the pathological and
therapeutic  effects.  Only  one  chapter
showed actual structures of the drugs; none
had diagrams illustrating the pathways in-
volved. In addition, almost all of the dis-
eases  mentioned  are  inborn  errors  of
metabolism. The geneticist is left to wonder
whether  small  molecules  can  be  used  in
other conditions such as prevalent neuro-de-
velopmental  disorders.  For  patients,  this
book provides valuable resources for self-
education about pharmacology and gate-
ways  to  search  for  clinical  trials  and
investigational drugs. Whether the examples
given are useful would likely vary among
patients. 
Ultimately, Small Molecular Therapy
for Genetic Diseases may prove to be the
most  beneficial  for  policy  makers.  The
book’s format and tone resemble government
progress reports, and it offers a concise and
convincing sampling of the fruits of the Or-
phan Drug Act while highlighting the ac-
complishments of their legislative endeavors. 
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